Danielle Harrill

Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo.

G. McComsey, M. O'riordan, N. Rizk, 2011, AIDS research and human retroviruses.

Subjective Clinical Lipoatrophy Assessment Correlates with DEXA-Measured Limb Fat

M. Gerschenson, G. McComsey, M. O'riordan, 2009, HIV clinical trials.

Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy.

G. McComsey, M. O'riordan, N. Rizk, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Mitochondrial Function, Inflammation, Fat and Bone in HIV Lipoatrophy: Randomized Study of Uridine Supplementation or Switch to Tenofovir

M. Gerschenson, G. McComsey, M. O'riordan, 2012, Antiviral therapy.

Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens

G. McComsey, M. O'riordan, N. Rizk, 2010, AIDS.

Endothelial Activation Markers Are Linked to HIV Status and Are Independent of Antiretroviral Therapy and Lipoatrophy

G. McComsey, M. O'riordan, N. Rizk, 2008, Journal of acquired immune deficiency syndromes.

Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection

M. Gerschenson, G. McComsey, M. O'riordan, 2008, Antiviral therapy.

Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults

G. McComsey, M. O'riordan, T. Carman, 2010, AIDS.

Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy.

G. McComsey, M. O'riordan, V. Dogra, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.